<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:56:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3480449" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:3480449</identifier>
        <datestamp>2012-10-30</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC3480449</article-id>
              <article-id pub-id-type="pmcid">PMC3480449</article-id>
              <article-id pub-id-type="pmc-uid">3480449</article-id>
              <article-id pub-id-type="pmid">23112868</article-id>
              <article-id pub-id-type="pmid">23112868</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-12-15319</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0047905</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v2">
                  <subject>Biology</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Neuroimaging</subject>
                      <subj-group>
                        <subject>Pet</subject>
                      </subj-group>
                    </subj-group>
                    <subj-group>
                      <subject>Molecular Neuroscience</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v2">
                  <subject>Medicine</subject>
                  <subj-group>
                    <subject>Mental Health</subject>
                    <subj-group>
                      <subject>Psychiatry</subject>
                      <subj-group>
                        <subject>Dementia</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Dementia</subject>
                      <subj-group>
                        <subject>Alzheimer Disease</subject>
                      </subj-group>
                    </subj-group>
                    <subj-group>
                      <subject>Neurodegenerative Diseases</subject>
                      <subject>Neuroimaging</subject>
                    </subj-group>
                  </subj-group>
                  <subj-group>
                    <subject>Radiology</subject>
                    <subj-group>
                      <subject>Nuclear medicine</subject>
                      <subj-group>
                        <subject>PET imaging</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment</article-title>
                <alt-title alt-title-type="running-head">Amyloid Deposition and Metabolism in Early MCI</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Liyong</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rowley</surname>
                    <given-names>Jared</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mohades</surname>
                    <given-names>Sara</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leuzy</surname>
                    <given-names>Antoine</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dauar</surname>
                    <given-names>Marina Tedeschi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shin</surname>
                    <given-names>Monica</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fonov</surname>
                    <given-names>Vladimir</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jia</surname>
                    <given-names>Jianping</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gauthier</surname>
                    <given-names>Serge</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosa-Neto</surname>
                    <given-names>Pedro</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1">
                    <sup>*</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>the Alzheimer’s Disease Neuroimaging Initiative</collab>
                </contrib>
              </contrib-group>
              <aff id="aff1">
                <label>1</label>
                <addr-line>Translational Neuroimaging Laboratory, Douglas Hospital, McGill University, Montreal, Quebec, Canada</addr-line>
              </aff>
              <aff id="aff2">
                <label>2</label>
                <addr-line>McGill Centre for Studies in Aging, McGill University, Montreal, Quebec, Canada</addr-line>
              </aff>
              <aff id="aff3">
                <label>3</label>
                <addr-line>Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China</addr-line>
              </aff>
              <aff id="aff4">
                <label>4</label>
                <addr-line>McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Ginsberg</surname>
                    <given-names>Stephen D.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Nathan Kline Institute and New York University School of Medicine, United States of America</addr-line>
              </aff>
              <author-notes>
                <corresp id="cor1">* E-mail: <email>pedro.rosa@mcgill.ca</email></corresp>
                <fn fn-type="COI-statement">
                  <p><bold>Competing Interests: </bold>The Alzheimer’s Disease Neuroimaging Initiative study received funding for data collection and sharing from commercial sources (Abbott; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC.; Medpace, Inc.; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. ). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <fn fn-type="con">
                  <p>Conceived and designed the experiments: LW PR. Performed the experiments: JR LW. Analyzed the data: JR LW PR. Contributed reagents/materials/analysis tools: SM MS VF PR JR. Wrote the paper: LW SM AL MD MS JJ SG PR.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2012</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>10</month>
                <year>2012</year>
              </pub-date>
              <volume>7</volume>
              <issue>10</issue>
              <elocation-id>e47905</elocation-id>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>5</month>
                  <year>2012</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>9</month>
                  <year>2012</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2012 Wu et al</copyright-statement>
                <copyright-year>2012</copyright-year>
                <copyright-holder>Wu et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
                </license>
              </permissions>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>The hypothetical model of dynamic biomarkers for Alzheimer’s disease (AD) describes high amyloid deposition and hypometabolism at the mild cognitive impairment (MCI) stage. However, it remains unknown whether brain amyloidosis and hypometabolism follow the same trajectories in MCI individuals. We used the concept of early MCI (EMCI) and late MCI (LMCI) as defined by the Alzheimer’s disease Neuroimaging Initiative (ADNI)-Go in order to compare the biomarker profile between EMCI and LMCI.</p>
                </sec>
                <sec>
                  <title>Objectives</title>
                  <p>To examine the global and voxel-based neocortical amyloid burden and metabolism among individuals who are cognitively normal (CN), as well as those with EMCI, LMCI and mild AD.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>In the present study, 354 participants, including CN (n = 109), EMCI (n = 157), LMCI (n = 39) and AD (n = 49), were enrolled between September 2009 and November 2011 through ADNI-GO and ADNI-2. Brain amyloid load and metabolism were estimated using [<sup>18</sup>F]AV45 and [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG) PET, respectively. Uptake ratio images of [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG were calculated by dividing the summed PET image by the median counts of the grey matter of the cerebellum and pons, respectively. Group differences of global [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG were analyzed using ANOVA, while the voxel-based group differences were estimated using statistic parametric mapping (SPM).</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>EMCI patients showed higher global [<sup>18</sup>F]AV45 retention compared to CN and lower uptake compared to LMCI. SPM detected higher [<sup>18</sup>F]AV45 uptake in EMCI compared to CN in the precuneus, posterior cingulate, medial and dorsal lateral prefrontal cortices, bilaterally. EMCI showed lower [<sup>18</sup>F]AV45 retention than LMCI in the superior temporal, inferior parietal, as well as dorsal lateral prefrontal cortices, bilaterally. Regarding to the global [<sup>18</sup>F]FDG, EMCI patients showed no significant difference from CN and a higher uptake ratio compared to LMCI. At the voxel level, EMCI showed higher metabolism in precuneus, hippocampus, entorhinal and inferior parietal cortices, as compared to LMCI.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>The present results indicate that brain metabolism remains normal despite the presence of significant amyloid accumulation in EMCI. These results suggest a role for anti-amyloid interventions in EMCI aiming to delay or halt the deposition of amyloid and related metabolism impairment.</p>
                </sec>
              </abstract>
              <funding-group>
                <funding-statement>The data analysis and writing of this paper were supported by Canadian institutes of Health Research (CIHR) (MOP-11-51-31), Alzheimer's Association (NIRG-08-92090), National Nature Science Foundation of China (NSFC) (3070024), Beijing Scientific and Technological New Star Program (2007B069), Nussia &amp; André Aisenstadt Foundation, and Fonds de la recherche en santé du Québec. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC.; Medpace, Inc.; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="http://www.fnih.org">www.fnih.org</ext-link>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by National Institutes of Health grants P30 AG010129 and K01 AG030514. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <page-count count="12"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec id="s1">
              <title>Introduction</title>
              <p>Alzheimer’s disease (AD) is characterized by a progressive accumulation of amyloid plaques, neurofibrillary tangles and neuronal depletion associated with a slow deterioration of cognition and functional status <xref rid="pone.0047905-Ballard1" ref-type="bibr">[1]</xref>. Numerous technological advances have made possible the quantification of amyloid accumulation and neurodegeneration in vivo using imaging and fluid biomarkers. In AD, biomarkers are classified as biomarkers of amyloid accumulation (i.e CSF Aβ<sub>1–42</sub>, [<sup>11</sup>C] Pittsburgh compound B (PIB) Positron Emission Tomography (PET), [<sup>18</sup>F]AV45 PET) and neurodegeneration (i.e CSF tau, [<sup>18</sup>F] fluorodeoxyglucose(FDG) PET and structural MRI) <xref rid="pone.0047905-Jack1" ref-type="bibr">[2]</xref>, <xref rid="pone.0047905-Wu1" ref-type="bibr">[3]</xref>.</p>
              <fig id="pone-0047905-g001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0047905.g001</object-id>
                <label>Figure 1</label>
                <caption>
                  <title>Summary of the imaging analysis methods.</title>
                </caption>
                <graphic xlink:href="pone.0047905.g001"/>
              </fig>
              <p>Jack <xref rid="pone.0047905-Jack1" ref-type="bibr">[2]</xref> proposed a dynamic biomarker model of Alzheimer’s based on vivo biomarker observations conducted in elderly normal individuals as well as in mild cognitive impairment (MCI) and AD dementia patients. Jacks’ model corroborates the amyloid cascade hypothesis, which posits that the accumulation of β-amyloid acts as an initiating ‘upstream’ event leading to ‘downstream’ events such neurodegeneration and subsequent cognitive impairment <xref rid="pone.0047905-Jack1" ref-type="bibr">[2]</xref>, <xref rid="pone.0047905-Hardy1" ref-type="bibr">[4]</xref>. The dynamic biomarker model of AD describes amyloid accumulation as the dominant biomarker in individuals with predementia, while the combination of amyloid accumulation and neurodegeneration characterize the dementia stage of AD <xref rid="pone.0047905-Jack1" ref-type="bibr">[2]</xref>. Moreover, this model predicts a plateau of amyloid accumulation and the onset of brain neurodegeneration as part of the MCI stage of AD <xref rid="pone.0047905-Jack1" ref-type="bibr">[2]</xref>. However, the dynamics of amyloid accumulation and neurodegeneration within the MCI stage are not well understood.</p>
              <p>Based on the data analysis conducted by the National Alzheimer’s Coordinating Center (NACC), the concept of early MCI (EMCI) and late MCI (LMCI) was first introduced by the Alzheimer’s Disease Neuroimaging Initiative (ADNI)-Go and ADNI-2 the distinction being made on the basis of modest or advanced impairment of delayed recall of logical memory <xref rid="pone.0047905-Aisen1" ref-type="bibr">[5]</xref>, <xref rid="pone.0047905-Weiner1" ref-type="bibr">[6]</xref>. The concept of EMCI will bridge the gap between normal elderly and LMCI subjects who are more amnestic than EMCI subjects <xref rid="pone.0047905-Aisen1" ref-type="bibr">[5]</xref>. It should be emphasized that while EMCI subjects still meet criteria for amnestic MCI, they represent a very early point in the clinical spectrum of AD <xref rid="pone.0047905-Aisen1" ref-type="bibr">[5]</xref>, <xref rid="pone.0047905-Weiner1" ref-type="bibr">[6]</xref>. The primary purpose of this classification in ADNI-Go and ADNI-2 is to elucidate the disease mechanisms present at a very early stage of AD (i.e. EMCI), with the attendant objective of improving the efficiency of disease-modification interventions <xref rid="pone.0047905-Aisen1" ref-type="bibr">[5]</xref>, <xref rid="pone.0047905-Weiner1" ref-type="bibr">[6]</xref>.</p>
              <p>Although several studies have focused on MCI and healthy elderly control, the status of brain amyloid deposition remains unknown at the early stage of MCI. The study from Australian Imaging Biomarkers and Lifestyle Research Group showed that the amyloid load of subjects with subjective cognitive impairment (SCI), a syndrome characterized by subjective memory complaint but no objective memory impairment, was similar to healthy elderly controls, and thus lower than levels found in MCI and AD <xref rid="pone.0047905-Chetelat1" ref-type="bibr">[7]</xref>. Longitudinal studies using [<sup>11</sup>C]PIB PET have shown no uptake differences during the follow-up of MCI patients who eventually converted to AD, suggesting that amyloid load plateau has been already reached in the late stage of MCI <xref rid="pone.0047905-Okello1" ref-type="bibr">[8]</xref>, <xref rid="pone.0047905-Koivunen1" ref-type="bibr">[9]</xref>. In fact, these findings suggest that LMCI may represent an intermediate state between cognitively normal individuals and MCI.</p>
              <table-wrap id="pone-0047905-t001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0047905.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Demographics and neuropsychological data for all groups.</title>
                </caption>
                <alternatives>
                  <graphic id="pone-0047905-t001-1" xlink:href="pone.0047905.t001"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                      <col align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">CN (n = 109)</td>
                        <td align="left" rowspan="1" colspan="1">EMCI (n = 157)</td>
                        <td align="left" rowspan="1" colspan="1">LMCI (n = 39)</td>
                        <td align="left" rowspan="1" colspan="1">AD (n = 49)</td>
                        <td align="left" rowspan="1" colspan="1"><italic>p</italic> value</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Gender (M/F)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">53/56</td>
                        <td align="left" rowspan="1" colspan="1">90/67</td>
                        <td align="left" rowspan="1" colspan="1">24/15</td>
                        <td align="left" rowspan="1" colspan="1">31/18</td>
                        <td align="left" rowspan="1" colspan="1">0.231</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Age (years)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">78.8±5.9</td>
                        <td align="left" rowspan="1" colspan="1">73.1±7.9<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">76.2±9.2<xref ref-type="table-fn" rid="nt105">d</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">75.6±7.8</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Education (years)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">16.4±2.8</td>
                        <td align="left" rowspan="1" colspan="1">16.0±2.7</td>
                        <td align="left" rowspan="1" colspan="1">16.4±3.2</td>
                        <td align="left" rowspan="1" colspan="1">16.7±2.8</td>
                        <td align="left" rowspan="1" colspan="1">0.304</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>MMSE</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">29.1±1.2</td>
                        <td align="left" rowspan="1" colspan="1">28.3±1.5<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">27.1±2.2<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">21.4±4.7<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>CDR-global</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0±0</td>
                        <td align="left" rowspan="1" colspan="1">0.5±0.1<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.5±0.1<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.0±0.4<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>CDR-sum of boxes</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.1±0.3</td>
                        <td align="left" rowspan="1" colspan="1">1.3±0.7<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.9±1.4<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">5.6±2.5<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>ADAS-cog</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">6.2±4.2</td>
                        <td align="left" rowspan="1" colspan="1">7.9±3.4<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">12.5±5.7<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">21.8±10.3<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Immediate recall of logical memory</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">14.8±3.6</td>
                        <td align="left" rowspan="1" colspan="1">11.3±3.0<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">6.5±3.4<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">4.2±3.0<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Delayed recall of logical memory</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">14.0±3.7</td>
                        <td align="left" rowspan="1" colspan="1">9.3±2.1<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">3.5±2.8<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">1.5±2.6<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Total immediate recall of</bold>
                          <bold>RAVLT (Trial 1 to 5)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">45.0±10.6</td>
                        <td align="left" rowspan="1" colspan="1">39.3±11.0<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">30.0±9.2<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">21.1±7.9<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Delayed recall of RAVLT</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">7.1±4.3</td>
                        <td align="left" rowspan="1" colspan="1">6.1±4.2<xref ref-type="table-fn" rid="nt103">b</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">2.2±2.8<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">0.7±2.3<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Recognition of RAVLT</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">12.8±2.3</td>
                        <td align="left" rowspan="1" colspan="1">12.2±2.9</td>
                        <td align="left" rowspan="1" colspan="1">9.1±3.8<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">6.5±4.3<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Trail making test A</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">34.6±14.6</td>
                        <td align="left" rowspan="1" colspan="1">36.4±13.1</td>
                        <td align="left" rowspan="1" colspan="1">44.4±24.0<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">65.9±38.9<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Trail making test B</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">82.2±37.1</td>
                        <td align="left" rowspan="1" colspan="1">99.8±57.0<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">140.1±77.8<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">189.6±83.7<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Verbal fluency (animal)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">20.8±5.8</td>
                        <td align="left" rowspan="1" colspan="1">18.8±5.0<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">16.3±5.8<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">11.0±4.4<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Boston naming test</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">27.8±4.4</td>
                        <td align="left" rowspan="1" colspan="1">27.2±3.5</td>
                        <td align="left" rowspan="1" colspan="1">24.9±6.8<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">23.2±6.5<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>FAQ</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">0.3±1.4</td>
                        <td align="left" rowspan="1" colspan="1">2.3±3.4<xref ref-type="table-fn" rid="nt102">a</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">5.0±5.4<xref ref-type="table-fn" rid="nt102">a c</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">15.8±6.5<xref ref-type="table-fn" rid="nt102">a c e</xref>
</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="nt101">
                    <p>All values are indicated as mean ± standard deviation except gender. p value indicates the value for the main effect of each group, as assessed with analyses of variance(ANOVA) for each variable except for gender, where a contingency chi-square was performed. Statistics for post hoc 2-by-2 group comparisons are provided as significant differences:</p>
                  </fn>
                  <fn id="nt102">
                    <label>a</label>
                    <p>from CN at p&lt;0.01;</p>
                  </fn>
                  <fn id="nt103">
                    <label>b</label>
                    <p>from CN at p&lt;0.05.</p>
                  </fn>
                  <fn id="nt104">
                    <label>c</label>
                    <p>from EMCI at p&lt;0.01;</p>
                  </fn>
                  <fn id="nt105">
                    <label>d</label>
                    <p>from EMCI at p&lt;0.05;</p>
                  </fn>
                  <fn id="nt106">
                    <label>e</label>
                    <p>from LMCI at p&lt;0.01.</p>
                  </fn>
                  <fn id="nt107">
                    <p>MMSE =  mini mental state examination; CDR = clinical dementia rating scale; ADAS  =  Alzheimer’s disease assessment scale; RAVLT =  Rey auditory verbal learning test; FAQ =  functional activities questionnaire.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The existence of synaptic degeneration in EMCI remains to be clarified, particularly due to the presence of mild but objective memory deficits in these individuals. [<sup>18</sup>F]FDG PET provides qualitative and quantitative estimates of the cerebral metabolic rate of glucose consumption, an index of synaptic functioning and density, which has been proven to be highly related with the clinical symptoms and taken as the symptoms-sensitive measurement in MCI <xref rid="pone.0047905-Landau1" ref-type="bibr">[10]</xref>, <xref rid="pone.0047905-Mosconi1" ref-type="bibr">[11]</xref>. Several studies have shown that MCI patients displayed cerebral hypometabolism bilaterally in the parieto-temporal areas, posterior cingulate cortex (PCC), medial temporal lobe, and even frontal lobe <xref rid="pone.0047905-Landau1" ref-type="bibr">[10]</xref>, <xref rid="pone.0047905-Langbaum1" ref-type="bibr">[12]</xref>–<xref rid="pone.0047905-Chen1" ref-type="bibr">[14]</xref>. It has been suggested that glucose metabolism is a sensitive measure of change in cognition and functional ability in MCI, and has value in predicting future cognitive decline <xref rid="pone.0047905-Landau1" ref-type="bibr">[10]</xref>, <xref rid="pone.0047905-Chen1" ref-type="bibr">[14]</xref>. Furthermore, MCI subjects with abnormal glucose metabolism were more likely to convert to AD than subjects who had normal glucose uptake <xref rid="pone.0047905-Landau1" ref-type="bibr">[10]</xref>–<xref rid="pone.0047905-Mosconi2" ref-type="bibr">[13]</xref>. Therefore, [<sup>18</sup>F]FDG PET provides significant information regarding the clinical characterization of synaptic dysfunction already present in EMCI <xref rid="pone.0047905-Wu1" ref-type="bibr">[3]</xref>, <xref rid="pone.0047905-Landau2" ref-type="bibr">[15]</xref>.</p>
              <p>The main objectives of the present study are thus to examine global and voxel-based neocortical amyloid burden and metabolism within separate groups of cognitively normal (CN), EMCI, LMCI, and AD. We intend to capture the dynamics of amyloid accumulation and neurodegeneration within the MCI stage. Assuming the premises of the amyloid cascade hypothesis, we expect a predominance of amyloid accumulation in the EMCI phase.</p>
            </sec>
            <sec sec-type="materials|methods" id="s2">
              <title>Materials and Methods</title>
              <sec id="s2a">
                <title>Database Description</title>
                <p>Participants were recruited between September 2009 and November 2011 through ADNI-GO and ADNI-2 from 56 centers in the USA and Canada <xref rid="pone.0047905-Weiner2" ref-type="bibr">[16]</xref>. The ethics committee at each participating site approved the study protocol. Written consent was obtained from all subjects participating in the study. Inclusion/exclusion criteria for ADNI studies are described elsewhere (<ext-link ext-link-type="uri" xlink:href="https://ida.loni.ucla.edu/login.jsp?project=ADNI">https://ida.loni.ucla.edu/login.jsp?project=ADNI</ext-link>).</p>
                <fig id="pone-0047905-g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0047905.g002</object-id>
                  <label>Figure 2</label>
                  <caption>
                    <title>[<sup>18</sup>F]AV45 (left) and [<sup>18</sup>F]FDG (right) average images obtained from controls (CN), early MCI (EMCI), late MCI (LMCI) and Alzheimer’s dementia patients (AD).</title>
                    <p>In [<sup>18</sup>F]AV45, there is a reduction of gray and white matter contrast in EMCI, LMCI and AD in comparison with CN. Note the PCC and IPC [<sup>18</sup>F]FDG SUVR reduction in LMCI and AD in comparison with CN.</p>
                  </caption>
                  <graphic xlink:href="pone.0047905.g002"/>
                </fig>
                <table-wrap id="pone-0047905-t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0047905.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Global [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG uptake in all groups.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone-0047905-t002-2" xlink:href="pone.0047905.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="center" span="1"/>
                        <col align="center" span="1"/>
                        <col align="center" span="1"/>
                        <col align="center" span="1"/>
                        <col align="center" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1">NC (n = 109)</td>
                          <td align="left" rowspan="1" colspan="1">EMCI (n = 157)</td>
                          <td align="left" rowspan="1" colspan="1">LMCI (n = 39)</td>
                          <td align="left" rowspan="1" colspan="1">AD (n = 49)</td>
                          <td align="left" rowspan="1" colspan="1"><italic>p</italic> value</td>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Global [<sup>18</sup>F]AV45 retention</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.28±0.25</td>
                          <td align="left" rowspan="1" colspan="1">1.40±0.33<xref ref-type="table-fn" rid="nt109">a</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.56±0.36<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.62±0.38<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Global [<sup>18</sup>F]FDG uptake</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.40±0.15</td>
                          <td align="left" rowspan="1" colspan="1">1.41±0.16</td>
                          <td align="left" rowspan="1" colspan="1">1.28±0.19<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.14±0.17<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Regional [<sup>18</sup>F]FDG uptake</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Left inferior parietal cortex</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.40±0.16</td>
                          <td align="left" rowspan="1" colspan="1">1.42±0.18</td>
                          <td align="left" rowspan="1" colspan="1">1.28±0.21<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.12±0.18<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Right inferior parietal cortex</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.45±0.17</td>
                          <td align="left" rowspan="1" colspan="1">1.46±0.19</td>
                          <td align="left" rowspan="1" colspan="1">1.33±0.23<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.16±0.22<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Left temporal lobe</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.35±0.23</td>
                          <td align="left" rowspan="1" colspan="1">1.33±0.16</td>
                          <td align="left" rowspan="1" colspan="1">1.21±0.18<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.08±0.17<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Right temporal lobe</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.33±0.15</td>
                          <td align="left" rowspan="1" colspan="1">1.38±0.17</td>
                          <td align="left" rowspan="1" colspan="1">1.28±0.18<xref ref-type="table-fn" rid="nt111">c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.14±0.18<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Left hippocampus</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.18±0.25</td>
                          <td align="left" rowspan="1" colspan="1">1.06±0.12<xref ref-type="table-fn" rid="nt109">a</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.96±0.15<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.88±0.14<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Right hippocampus</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.01±0.11</td>
                          <td align="left" rowspan="1" colspan="1">1.02±0.12</td>
                          <td align="left" rowspan="1" colspan="1">0.92±0.14<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">0.84±0.18<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Left posterior cingulate cortex</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.58±0.18</td>
                          <td align="left" rowspan="1" colspan="1">1.61±0.20</td>
                          <td align="left" rowspan="1" colspan="1">1.44±0.23<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.27±0.21<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Right posterior cingulate cortex</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">1.57±0.19</td>
                          <td align="left" rowspan="1" colspan="1">1.59±0.19</td>
                          <td align="left" rowspan="1" colspan="1">1.42±0.23<xref ref-type="table-fn" rid="nt109">a c</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">1.25±0.23<xref ref-type="table-fn" rid="nt109">a c e</xref>
</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="nt108">
                      <p>All values are indicated as mean ± standard deviation. p value indicates the value for the main effect of each group, as assessed with analyses of variance(ANOVA) for each variable. Statistics for post hoc 2-by-2 group comparisons are provided as significant differences:</p>
                    </fn>
                    <fn id="nt109">
                      <label>a</label>
                      <p>from CN at p&lt;0.01;</p>
                    </fn>
                    <fn id="nt110">
                      <label>b</label>
                      <p>from CN at p&lt;0.05.</p>
                    </fn>
                    <fn id="nt111">
                      <label>c</label>
                      <p>from EMCI at p&lt;0.01;</p>
                    </fn>
                    <fn id="nt112">
                      <label>d</label>
                      <p>from EMCI at p&lt;0.05;</p>
                    </fn>
                    <fn id="nt113">
                      <label>e</label>
                      <p>from LMCI at p&lt;0.01.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>From the ADNI-Go and ADNI-2 dataset, we selected all participants between 55–90 (inclusive) years of age who had completed, in the same visit, the following clinical, imaging and neuropsychological assessments: MRI, [<sup>18</sup>F]AV45 PET, [<sup>18</sup>F]FDG PET, Mini Mental State Examination (MMSE), Clinical Dementia Rating scale (CDR), Wechsler Memory Scale Logical Memory II, Alzheimer’s disease assessment scale (ADAS)-cog, Rey auditory verbal learning test (RAVLT), 30-item Boston Naming Test, Category Fluency (animal), and Trails Making Test (A &amp; B), as well as the functional activities questionnaire (FAQ). Selected individuals were classified as CN, LMCI, EMCI and AD according to clinical and behavioral measures provided by ADNI at the time of the imaging study. Individual with Modified Hachinski Ischemia Score higher than four points were excluded during the screening phase. Furthermore, subjects with imaging evidence of clinically significant vascular changes were excluded from this analysis.</p>
                <fig id="pone-0047905-g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0047905.g003</object-id>
                  <label>Figure 3</label>
                  <caption>
                    <title>Comparison of global neocortical [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG uptake among each group.</title>
                    <p>Dissociation of amyloid deposition and hypometabolism in EMCI was shown by significant group difference in term of [<sup>18</sup>F]AV45 without group difference of [<sup>18</sup>F]FDG in EMCI versus CN. # means significant difference between groups (<italic>p</italic>&lt;0.01), while NS represents no significant group difference(<italic>p&gt;</italic>0.05).</p>
                  </caption>
                  <graphic xlink:href="pone.0047905.g003"/>
                </fig>
                <fig id="pone-0047905-g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0047905.g004</object-id>
                  <label>Figure 4</label>
                  <caption>
                    <title>Images represent statistical parametric mapping depicting (spectrum color bars) t-statistical contrast overlaid on a group structural MRI. Right images represent voxel-based statistical differences comparing [<sup>18</sup>F]AV45 retention (EMCI &gt; CN).</title>
                    <p>Left images represents voxel-based statistical differences comparing [<sup>18</sup>F]FDG uptake (EMCI &lt; CN).</p>
                  </caption>
                  <graphic xlink:href="pone.0047905.g004"/>
                </fig>
              </sec>
              <sec id="s2b">
                <title>Classification Criteria</title>
                <p>The criteria for CN included an MMSE score ranging between 24–30 (inclusive), and a CDR score of 0 (non-demented) <xref rid="pone.0047905-Berg1" ref-type="bibr">[17]</xref>, <xref rid="pone.0047905-Folstein1" ref-type="bibr">[18]</xref>. The criteria for EMCI included the presence of a subjective memory complaint, with an MMSE score between 24–30 (inclusive), objective memory loss as shown on scores on delayed recall of one paragraph from the Wechsler Memory Scale Logical Memory II (adjusted for age and education; ≥16 years: 9–11; 8–15 years: 5–9; 0–7 years: 3–6), a CDR of 0.5, preserved activities of daily living, and an absence of dementia <xref rid="pone.0047905-Aisen1" ref-type="bibr">[5]</xref>, <xref rid="pone.0047905-Wechsler1" ref-type="bibr">[19]</xref>. The criteria for LMCI subjects included the same criteria as EMCI, except for the greater objective memory loss measured by scores on delayed recall of Wechsler Memory Scale Logical Memory II (adjusted by age and education; ≥16 years: ≤8; 8–15 years: ≤4; 0–7 years: ≤2) <xref rid="pone.0047905-Aisen1" ref-type="bibr">[5]</xref>. In addition to the NINCDS/ADRDA criteria for probable AD, mild AD dementia subjects had MMSE scores between 20–26 (inclusive) and a CDR of 0.5 or 1.0 <xref rid="pone.0047905-Tierney1" ref-type="bibr">[20]</xref>.</p>
                <fig id="pone-0047905-g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0047905.g005</object-id>
                  <label>Figure 5</label>
                  <caption>
                    <title>Images represent statistical parametric mapping depicting (spectrum color bars) t-statistical contrast overlaid on a group structural MRI.</title>
                    <p>Right images represent voxel-based statistical differences comparing [<sup>18</sup>F]AV45 retention (LMCI &gt; EMCI). Left images represents voxel-based statistical differences comparing [<sup>18</sup>F]FDG uptake (LMCI &lt; EMCI).</p>
                  </caption>
                  <graphic xlink:href="pone.0047905.g005"/>
                </fig>
                <fig id="pone-0047905-g006" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0047905.g006</object-id>
                  <label>Figure 6</label>
                  <caption>
                    <title>Images represent statistical parametric mapping depicting (spectrum color bars) t-statistical contrast overlaid on a group structural MRI.</title>
                    <p>Right images represent voxel-based statistical differences comparing [<sup>18</sup>F]AV45 retention (AD &gt; LMCI). Left images represents voxel-based statistical differences comparing [<sup>18</sup>F]FDG uptake (AD &lt; LMCI).</p>
                  </caption>
                  <graphic xlink:href="pone.0047905.g006"/>
                </fig>
              </sec>
              <sec id="s2c">
                <title>PET Methods</title>
                <sec id="s2c1">
                  <title>PET image acquisition</title>
                  <p>A detailed description of the [<sup>18</sup>F] AV45 and [<sup>18</sup>F]FDG PET image acquisition can be found at <ext-link ext-link-type="uri" xlink:href="http://www.adni-info.org">http://www.adni-info.org</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml">http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml</ext-link>.</p>
                </sec>
                <sec id="s2c2">
                  <title>PET imaging processing</title>
                  <p>The image processing is summarized in <xref ref-type="fig" rid="pone-0047905-g001">Figure 1</xref>. In brief, T1 MRIs were corrected for non-uniformities and skull stripped. Subsequently, skull-stripped uncorrected MRIs were then linearly registered to the MNI space using mutual information and 9 parameters of transformation. Deformation fields (4 mm) were calculated for each individual scan. Next, the non-linearly registered MRIs were classified into grey matter (GM), white matter (WM) and CSF using the INSECT algorithm. Finally, ANIMAL algorithm extracted the cerebellum, hippocampi as well as the temporal, prefrontal, inferior parietal, anterior and posterior cingulate cortices.</p>
                </sec>
                <sec id="s2c3">
                  <title>Estimation of parametric images</title>
                  <p>Individual [<sup>18</sup>F]AV45 images were registered (see bellow) to the respective structural MRI using a 6 parameter mutual information algorithm. Individual brain regions were subsequently resampled to the PET native space. Uptake ratio (UR) images were calculated by dividing PET image by the median cerebellar grey matter count. Individual UR images were subsequently registered to the MNI space using the respective deformation fields. The images were then blurred using a 6 mm FWHM Gaussian kernel. [<sup>18</sup>F]FDG UR images were created in the same way as the [<sup>18</sup>F]AV45 except summed images were obtained using the pons as a reference region.</p>
                </sec>
                <sec id="s2c4">
                  <title>Estimation of global values</title>
                  <p>Global cortical [<sup>18</sup>F]AV45 retention was obtained from the median UR of the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate and posterior cingulate/precuneus for each subject <xref rid="pone.0047905-Jack2" ref-type="bibr">[21]</xref>. Global [<sup>18</sup>F]FDG uptake was formed by the median UR from the inferior parietal cortex, posterior cingulated gyrus, and temporal lobe including the hippocampus.</p>
                </sec>
              </sec>
              <sec id="s2d">
                <title>Statistical Methods</title>
                <p>Statistical tests were performed using SPSS 20.0 statistical software. Statistical significance was set at <italic>p</italic>≤0.05.</p>
                <p>First, between-group comparisons of demographic and neuropsychological data were assessed using one-way ANOVA or chi-square (for gender) tests accordingly. Pairwise comparisons of CN, EMCI, LMCI and AD subjects were performed using an independence sample t-test.</p>
                <p>Secondly, we interrogated [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG UR at the voxel level in order to localize clusters of significant group difference. Voxel based group statistical differences were obtained by contrasting blurred [<sup>18</sup>F]FDG and [<sup>18</sup>F]AV45 UR images from all groups, after correcting for age, (2 at a time 6 total contrasts) using RMINC. RMINC is an imaging package that allows images files in the MINC to be analyzed with the powerful statistical environment R-statistic (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link>). False discovery rate was used to threshold results for multiple comparisons <xref rid="pone.0047905-Worsley1" ref-type="bibr">[22]</xref>. Corrected threshold of significance was p&lt;0.01 a t&gt;3.5.</p>
              </sec>
            </sec>
            <sec id="s3">
              <title>Results</title>
              <sec id="s3a">
                <title>Demographic and Neuropsychological Data</title>
                <p>Three hundred fifty-four participants, including CN (n = 109), EMCI (n = 157), LMCI (n = 39) and AD (n = 49), were included in the present study. Demographic data and neuropsychological test scores are shown in <xref ref-type="table" rid="pone-0047905-t001">Table 1</xref>. No significant differences in gender and education were noted among all groups. However, the age of EMCI is younger than CN and LMCI (<italic>p</italic>&lt;0.001, t = 6.372, df = 263 for EMCI versus CN; <italic>p</italic> = 0.032, t = 2.159, df = 194 for EMCI versus LMCI).</p>
                <p>When the four groups (CN, EMCI, LMCI and AD) were compared, significant differences were found for all neuropsychological scores (<italic>p</italic>&lt;0.001). When compared to CN, EMCI individuals showed significant impairment on the majority of neuropsychological assessment measures, with the exception of trail making test A, recognition of AVLT and Boston naming test. The neuropsychological scores were significantly lower in EMCI patients compared to both LMCI and AD.</p>
              </sec>
              <sec id="s3b">
                <title>Global Cortical [<sup>18</sup>F]AV45 Retention and [<sup>18</sup>F]FDG Uptake in Each Group</title>
                <p>The global [<sup>18</sup>F]AV45 retention ratio values in each group are shown in <xref ref-type="table" rid="pone-0047905-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0047905-g002">Figure 2</xref>. EMCI patients showed significantly higher global [<sup>18</sup>F]AV45 retention compared to CN (1.40 versus 1.28, <italic>p</italic>&lt;0.01) and lower amyloid retention compared to LMCI (1.40 versus 1.56, <italic>p</italic>&lt;0.01). No significant differences were found between LMCI subjects and AD patients (1.56 versus 1.62, <italic>p</italic> = 0.39). Significance levels remained unchanged after applying age as a covariate.</p>
                <p>The global and regional [<sup>18</sup>F]FDG uptake ratios in each group are shown in <xref ref-type="table" rid="pone-0047905-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0047905-g002">Figure 2</xref>. No significant differences in global [<sup>18</sup>F]FDG uptake ratio were found between EMCI subjects and CN individuals (1.42 versus 1.40, <italic>p</italic> = 0.233). In contrast, LMCI patients showed significantly lower global [<sup>18</sup>F]FDG uptake ratio compared to EMCI (1.28 versus 1.42, <italic>p</italic>&lt;0.01) yet higher than AD (1.28 versus 1.14, <italic>p</italic>&lt;0.01). Significance levels of group difference remained unchanged by the correction of age.</p>
              </sec>
              <sec id="s3c">
                <title>Voxel-based Group Comparisons of [<sup>18</sup>F]AV45 Retention and [<sup>18</sup>F]FDG Uptake</title>
                <p>[<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG average group images are represented in <xref ref-type="fig" rid="pone-0047905-g003">figure 3</xref>. SPM detected significantly higher [<sup>18</sup>F]AV45 retention in the EMCI subjects compared to CN individuals, mainly in the medial and ventral part of frontal lobe (e.g. medial prefrontal cortex, ventral lateral prefrontal cortex), anterior cingulate cortex (ACC), and posterior cingulate cortex (PCC)/precuneus (<xref ref-type="fig" rid="pone-0047905-g004">figure 4</xref>). Compared to EMCI, LMCI subjects showed significantly higher [<sup>18</sup>F]AV45 retention, most remarkably in dorsal lateral prefrontal cortex (DLPFC), and inferior parietal cortex (IPC), as well as middle temporal cortex (<xref ref-type="fig" rid="pone-0047905-g005">figure 5</xref>). Voxel-based analyses revealed a small but significant cluster with higher [<sup>18</sup>F]AV45 retention in right precentral gyrus in AD patients in contrast to LMCI individuals (<xref ref-type="fig" rid="pone-0047905-g006">figure 6</xref>).</p>
                <p>SPM analyses revealed a small but significant cluster with lower [<sup>18</sup>F]FDG uptake in middle temporal gyrus in EMCI patients in contrast to CN (<xref ref-type="fig" rid="pone-0047905-g004">figure 4</xref>). Compared to EMCI, LMCI subjects showed significantly lower metabolism, most remarkably in bilateral posterior cingulate cortex (PCC)/precuneus, hippocampus and middle temporal gyrus, and, to a lesser extent, in the inferior parietal cortex (IPC) (<xref ref-type="fig" rid="pone-0047905-g005">figure 5</xref>). In contrast to LMCI, AD patients displayed significantly lower [<sup>18</sup>F]FDG uptake mainly in inferior parietal cortex (IPC) and posterior cingulate cortex (PCC)/precuneus, as well as in the temporal lobe (<xref ref-type="fig" rid="pone-0047905-g006">figure 6</xref>).</p>
              </sec>
            </sec>
            <sec id="s4">
              <title>Discussion</title>
              <p>The present study explored, at a global and voxel-based level, brain cortical amyloid burden and metabolism using [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG, respectively, within separate groups of CN, EMCI, LMCI and AD. We found that the global [<sup>18</sup>F]AV45 retention level in EMCI is intermediate between that of CN and LMCI, whereas no group differences in global amyloid retention were found between LMCI and AD. As for the global [<sup>18</sup>F]FDG uptake ratio, EMCI did not show significant differences when compared to CN, while hypometabolism was noticed in LMCI but not in EMCI. In terms of voxel based cortical [<sup>18</sup>F]AV45 retention, the main finding is that compared to CN, EMCI is associated with a significantly diffuse increased brain amyloid burden. In contrast, only one small hypometabolic cluster was found in the SPM contrast [EMCI &lt; CN], though significant decrements in metabolism were noticed in PCC/precuneus and hippocampus in LMCI versus EMCI.</p>
              <sec id="s4a">
                <title>Amyloid Deposition in EMCI</title>
                <p>Abnormal amyloid load is detected in nearly a third of individuals older than 65 y.o. It is relatively well established that abnormal amyloid load is linked to APOE4 status as well as age <xref rid="pone.0047905-Morris1" ref-type="bibr">[23]</xref>. A fraction of these individuals might carry, as recently described, reactive amyloidosis <xref rid="pone.0047905-Soscia1" ref-type="bibr">[24]</xref>. However, the interpretation of these finding remains elusive given the lack of long term longitudinal studies of cognitively normal individuals carriers of high load of amyloid pathology. The amyloid load of subjects with subjective cognitive impairment (SCI) was similar to that found in healthy elderly controls, remaining at a lower level compared with MCI and AD <xref rid="pone.0047905-Chetelat1" ref-type="bibr">[7]</xref>. Longitudinal studies of non-demented older adults have shown that amyloid deposition increases slowly from cognitive normality and precedes cognitive impairment <xref rid="pone.0047905-Villemagne1" ref-type="bibr">[25]</xref>, <xref rid="pone.0047905-Sojkova1" ref-type="bibr">[26]</xref>. Some of these reports have demonstrated an annual increase of amyloid deposition, in terms of [<sup>11</sup>C]PIB retention, of 0.9% per year in non-demented older adults, with the amyloid deposition localized to prefrontal, parietal, lateral temporal, and occipital cortices as well as anterior and posterior cingulate cortices <xref rid="pone.0047905-Sojkova1" ref-type="bibr">[26]</xref>. However, it is not known how early in the disease course amyloid deposition can be detected. In the present study, the amyloid burden associated with EMCI is relatively lower than LMCI and higher compared to CN. This finding indicates that amyloid deposition characterizes EMCI stage and will possibly continue to accumulate during the progression from EMCI to LMCI <xref rid="pone.0047905-Aizenstein1" ref-type="bibr">[27]</xref>.</p>
                <p>A 2 year follow-up longitudinal [<sup>11</sup>C]PIB PET study showed amyloid load in mild AD remained relatively stable, suggesting that amyloid deposition in the brain might reach a plateau before the early clinical stages of AD <xref rid="pone.0047905-Engler1" ref-type="bibr">[28]</xref>. The concept of amyloid plateau has been further supported by cross sectional studies showing similar amyloid load between MCI and AD, <xref rid="pone.0047905-Chetelat1" ref-type="bibr">[7]</xref>, <xref rid="pone.0047905-Jack3" ref-type="bibr">[29]</xref>, <xref rid="pone.0047905-Weigand1" ref-type="bibr">[30]</xref>. Interestingly, other longitudinal studies of MCI cohorts also suggest that the baseline amyloid load could be a predictor of dementia conversion <xref rid="pone.0047905-Okello1" ref-type="bibr">[8]</xref>, <xref rid="pone.0047905-Koivunen1" ref-type="bibr">[9]</xref>, <xref rid="pone.0047905-Jack2" ref-type="bibr">[21]</xref>, <xref rid="pone.0047905-Forsberg1" ref-type="bibr">[31]</xref>. Together with the previous studies, the absence of group differences in terms of global amyloid retention between LMCI and AD in the present study indicates that amyloid load reaches a plateau at LMCI but not EMCI stage <xref rid="pone.0047905-Koivunen1" ref-type="bibr">[9]</xref>, <xref rid="pone.0047905-Jack2" ref-type="bibr">[21]</xref>, <xref rid="pone.0047905-Jack3" ref-type="bibr">[29]</xref>. Therefore, the findings in the present study further support the dynamic biomarker model of AD, which posits that the amyloid plateau has already been reached in MCI <xref rid="pone.0047905-Jack1" ref-type="bibr">[2]</xref>.</p>
                <p>Interestingly, we found higher amyloid load in ACC/PCC and the inferior part of the frontal lobe in EMCI versus CN, along with higher amyloid burden in temporal and parietal lobe, and superior part of frontal lobe in LMCI versus EMCI. This regional pattern of amyloid deposition is consistent with the pathological process described by autopsy studies where amyloid deposition progress from middle to lateral, from anterior to posterior and from basal to top of the brain <xref rid="pone.0047905-Braak1" ref-type="bibr">[32]</xref>.</p>
              </sec>
              <sec id="s4b">
                <title>Brain Metabolism in EMCI</title>
                <p>The lack of metabolism decrements in EMCI versus CN is possibly associated with a small magnitude in the [<sup>18</sup>F]FDG metabolism present in early MCI stages as well as the etiological variability within the MCI group. Indeed, variability across studies regarding brain metabolism in MCI occur due to the differences on the diagnostic criteria as well as the variations in clinical severity of the MCI subjects enrolled <xref rid="pone.0047905-Langbaum1" ref-type="bibr">[12]</xref>, <xref rid="pone.0047905-Mosconi2" ref-type="bibr">[13]</xref>, <xref rid="pone.0047905-DelSole1" ref-type="bibr">[33]</xref>, <xref rid="pone.0047905-Li1" ref-type="bibr">[34]</xref>. Our estimates of global [<sup>18</sup>F]FDG excluded metabolically stable brain regions in AD in order to increase the sensitivity for detecting hypometabolism. In fact, [<sup>18</sup>F]FDG-PET studies have shown that medial temporal lobe (MTL), inferior parietal cortex and PCC are vulnerable to hypometabolism and thus appropriated for the identification of MCI, while the utility of other cortical deficits was deemed debatable <xref rid="pone.0047905-Li1" ref-type="bibr">[34]</xref>–<xref rid="pone.0047905-Mosconi3" ref-type="bibr">[36]</xref>. Moreover, studies focusing on the temporal aspects of progression from MCI to AD conversion have suggested that impairment of [<sup>18</sup>F]FDG uptake in temporoparietal association cortices predicted a rapid progression to dementia in MCI patients and could, therefore, serve as a biomarker for the diagnosis of prodromal AD <xref rid="pone.0047905-Landau1" ref-type="bibr">[10]</xref>, <xref rid="pone.0047905-Landau2" ref-type="bibr">[15]</xref>, <xref rid="pone.0047905-Herholz1" ref-type="bibr">[37]</xref>.</p>
                <p>The most interesting finding of our study is a specific dissociation between brain amyloid deposition and metabolism in EMCI stage. The amyloid load in absence of hypometabolism further supports the view that amyloid deposition precedes neuronal dysfunction in the early stage of MCI <xref rid="pone.0047905-Lowe1" ref-type="bibr">[38]</xref>. Similarly, the dissociation between amyloid load and metabolic reductions was also demonstrated by another study, in which only 54% of the [<sup>11</sup>C]PIB positive MCI patients also showed [<sup>18</sup>F]FDG reductions <xref rid="pone.0047905-Li1" ref-type="bibr">[34]</xref>.</p>
                <p>Lower [<sup>18</sup>F]FDG uptake, primarily in bilateral PCC/precuneus and hippocampus, in LMCI versus EMCI supports that brain metabolic dysfunction develop in these regions during the MCI stage and thus might serve as a biomarker to monitor the disease progression from EMCI to LMCI. The present study also raises the question about the role of amyloid plaque formation in the synaptic dysfunction <xref rid="pone.0047905-Edison1" ref-type="bibr">[39]</xref>. The group differences between EMCI and LMCI reported in this study support the assumption that brain amyloid deposition is linked with synaptic damage, especially in the PCC/precuneus and hippocampus during the MCI stage, which is of paramount importance vis à vis the use of [<sup>18</sup>F]FDG PET in clinical trials. Neuronal toxicity might be mediated by high oligomeric forms of Aβ<sub>1–42</sub>
<xref rid="pone.0047905-Renner1" ref-type="bibr">[40]</xref>–<xref rid="pone.0047905-Lacor1" ref-type="bibr">[41]</xref>.</p>
              </sec>
              <sec id="s4c">
                <title>Implications for the Clinical Trial of Disease Modifying Prevention</title>
                <p>It is accepted that the use of disease-modifying treatments during the dementia stage of AD may not be adequate, since extensive brain damage has already been established and that the best target population for disease-modifying therapy are those at the MCI stage <xref rid="pone.0047905-Wu1" ref-type="bibr">[3]</xref>, <xref rid="pone.0047905-Cummings1" ref-type="bibr">[42]</xref>. It is reasonable to assume that the maximal benefit of disease-modifying therapy targeting the amyloid pathophysiologic mechanisms underlying AD should be obtained in the earlier stage before the amyloid load reaches a plateau and irreversible pathological changes occur <xref rid="pone.0047905-Wu1" ref-type="bibr">[3]</xref>. The findings in the present study therefore have several important implications. Firstly, the classification of EMCI is a useful concept in terms of early intervention with anti-amyloid therapy. In other words, anti-amyloid therapy should be administered in EMCI instead of LMCI in order to maximize the likelihood of slowing or halt amyloid deposition and thus the downstream pathophysiological processes including the decline of brain metabolism. It is likely that intervention in the late stage of disease would have to target other pathological processes since the amyloid load will have reached a plateau at LMCI stage <xref rid="pone.0047905-Chetelat1" ref-type="bibr">[7]</xref>. Secondly, amyloid imaging can be utilized as a diagnostic biomarker for identifying EMCI individuals, whereas [<sup>18</sup>F]FDG PET imaging might be used as an endpoint biomarker to monitor the rate of disease progression and detect treatment effects in clinical trials for EMCI <xref rid="pone.0047905-Wu1" ref-type="bibr">[3]</xref>.</p>
              </sec>
              <sec id="s4d">
                <title>Limitations of the Study</title>
                <p>There are several limitations in the interpretation of the present study, which should be acknowledged. Firstly, since the ADNI-GO was initiated 2 years ago and [<sup>18</sup>F]AV45 and [<sup>18</sup>F]FDG imaging are to be performed only every two years from baseline, the present data are cross-sectional. Thus, the follow-up of these EMCI patients in ADNI-2 will be of paramount importance to record the real progress of amyloid deposition and metabolism. Secondly, although EMCI patients were carefully selected according to objective memory impairment and exclusion of any significant neurological disease other than suspected incipient AD, EMCI are still likely to encompass heterogeneous etiologies, thereby masking AD-specific findings to some degree. Since no genetic data of new subjects recruited from ADNI-GO and ADNI-2 are currently available for analysis, the impact of Apoe4 on the amyloid deposition is not included in the present study <xref rid="pone.0047905-Reiman1" ref-type="bibr">[43]</xref>. Finally, despite of the optimal binding to the fibrillary Aβ<sub>1–42</sub> deposits, [<sup>18</sup>F]AV45 does not reveal hippocampal Aβ<sub>1–42</sub> deposits.</p>
              </sec>
              <sec id="s4e">
                <title>Conclusion</title>
                <p>The present study explored the global and voxel-based cortical amyloid burden and metabolism within separate groups of CN, EMCI, LMCI, and AD. The present results indicate a dissociation between amyloid deposition and hypometabolism in EMCI. These results highlight the EMCI period as an optimal period for intervention with anti-amyloid therapies.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0047905-Ballard1">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Ballard</surname><given-names>C</given-names></name>, <name><surname>Gauthier</surname><given-names>S</given-names></name>, <name><surname>Corbett</surname><given-names>A</given-names></name>, <name><surname>Brayne</surname><given-names>C</given-names></name>, <name><surname>Aarsland</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Alzheimer’s disease</article-title>. <source>Lancet</source>
<volume>377</volume>: <fpage>1019</fpage>–<lpage>1031</lpage>.<pub-id pub-id-type="pmid">21371747</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Jack1">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name><surname>Knopman</surname><given-names>DS</given-names></name>, <name><surname>Jagust</surname><given-names>WJ</given-names></name>, <name><surname>Shaw</surname><given-names>LM</given-names></name>, <name><surname>Aisen</surname><given-names>PS</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade</article-title>. <source>Lancet Neurol</source>
<volume>9</volume>: <fpage>119</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">20083042</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Wu1">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>L</given-names></name>, <name><surname>Rosa-Neto</surname><given-names>P</given-names></name>, <name><surname>Gauthier</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>Use of biomarkers in clinical trials of Alzheimer disease: from concept to application</article-title>. <source>Mol Diagn Ther</source>
<volume>15</volume>: <fpage>313</fpage>–<lpage>325</lpage>.<pub-id pub-id-type="pmid">22188635</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Hardy1">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Hardy</surname><given-names>JA</given-names></name>, <name><surname>Higgins</surname><given-names>GA</given-names></name> (<year>1992</year>) <article-title>Alzheimer’s disease: the amyloid cascade hypothesis</article-title>. <source>Science</source>
<volume>256</volume>: <fpage>184</fpage>–<lpage>185</lpage>.<pub-id pub-id-type="pmid">1566067</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Aisen1">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Aisen</surname><given-names>PS</given-names></name>, <name><surname>Petersen</surname><given-names>RC</given-names></name>, <name><surname>Donohue</surname><given-names>MC</given-names></name>, <name><surname>Gamst</surname><given-names>A</given-names></name>, <name><surname>Raman</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans</article-title>. <source>Alzheimers Dement</source>
<volume>6</volume>: <fpage>239</fpage>–<lpage>246</lpage>.<pub-id pub-id-type="pmid">20451872</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Weiner1">
                <label>6</label>
                <mixed-citation publication-type="other">Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, <etal>et al</etal>. (2010) The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6: 202–211 e207.</mixed-citation>
              </ref>
              <ref id="pone.0047905-Chetelat1">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Chetelat</surname><given-names>G</given-names></name>, <name><surname>Villemagne</surname><given-names>VL</given-names></name>, <name><surname>Bourgeat</surname><given-names>P</given-names></name>, <name><surname>Pike</surname><given-names>KE</given-names></name>, <name><surname>Jones</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Relationship between atrophy and beta-amyloid deposition in Alzheimer disease</article-title>. <source>Ann Neurol</source>
<volume>67</volume>: <fpage>317</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">20373343</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Okello1">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Okello</surname><given-names>A</given-names></name>, <name><surname>Koivunen</surname><given-names>J</given-names></name>, <name><surname>Edison</surname><given-names>P</given-names></name>, <name><surname>Archer</surname><given-names>HA</given-names></name>, <name><surname>Turkheimer</surname><given-names>FE</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study</article-title>. <source>Neurology</source>
<volume>73</volume>: <fpage>754</fpage>–<lpage>760</lpage>.<pub-id pub-id-type="pmid">19587325</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Koivunen1">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Koivunen</surname><given-names>J</given-names></name>, <name><surname>Scheinin</surname><given-names>N</given-names></name>, <name><surname>Virta</surname><given-names>JR</given-names></name>, <name><surname>Aalto</surname><given-names>S</given-names></name>, <name><surname>Vahlberg</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study</article-title>. <source>Neurology</source>
<volume>76</volume>: <fpage>1085</fpage>–<lpage>1090</lpage>.<pub-id pub-id-type="pmid">21325653</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Landau1">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Landau</surname><given-names>SM</given-names></name>, <name><surname>Harvey</surname><given-names>D</given-names></name>, <name><surname>Madison</surname><given-names>CM</given-names></name>, <name><surname>Koeppe</surname><given-names>RA</given-names></name>, <name><surname>Reiman</surname><given-names>EM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI</article-title>. <source>Neurobiol Aging</source>
<volume>32</volume>: <fpage>1207</fpage>–<lpage>1218</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0047905-Mosconi1">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Mosconi</surname><given-names>L</given-names></name>, <name><surname>Berti</surname><given-names>V</given-names></name>, <name><surname>Glodzik</surname><given-names>L</given-names></name>, <name><surname>Pupi</surname><given-names>A</given-names></name>, <name><surname>De Santi</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging</article-title>. <source>J Alzheimers Dis</source>
<volume>20</volume>: <fpage>843</fpage>–<lpage>854</lpage>.<pub-id pub-id-type="pmid">20182025</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Langbaum1">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Langbaum</surname><given-names>JB</given-names></name>, <name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Lee</surname><given-names>W</given-names></name>, <name><surname>Reschke</surname><given-names>C</given-names></name>, <name><surname>Bandy</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)</article-title>. <source>Neuroimage</source>
<volume>45</volume>: <fpage>1107</fpage>–<lpage>1116</lpage>.<pub-id pub-id-type="pmid">19349228</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Mosconi2">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Mosconi</surname><given-names>L</given-names></name>, <name><surname>Tsui</surname><given-names>WH</given-names></name>, <name><surname>De Santi</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Rusinek</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis</article-title>. <source>Neurology</source>
<volume>64</volume>: <fpage>1860</fpage>–<lpage>1867</lpage>.<pub-id pub-id-type="pmid">15955934</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Chen1">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Langbaum</surname><given-names>JB</given-names></name>, <name><surname>Fleisher</surname><given-names>AS</given-names></name>, <name><surname>Ayutyanont</surname><given-names>N</given-names></name>, <name><surname>Reschke</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Twelve-month metabolic declines in probable Alzheimer’s disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer’s Disease Neuroimaging Initiative</article-title>. <source>Neuroimage</source>
<volume>51</volume>: <fpage>654</fpage>–<lpage>664</lpage>.<pub-id pub-id-type="pmid">20202480</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Landau2">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Landau</surname><given-names>SM</given-names></name>, <name><surname>Harvey</surname><given-names>D</given-names></name>, <name><surname>Madison</surname><given-names>CM</given-names></name>, <name><surname>Reiman</surname><given-names>EM</given-names></name>, <name><surname>Foster</surname><given-names>NL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Comparing predictors of conversion and decline in mild cognitive impairment</article-title>. <source>Neurology</source>
<volume>75</volume>: <fpage>230</fpage>–<lpage>238</lpage>.<pub-id pub-id-type="pmid">20592257</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Weiner2">
                <label>16</label>
                <mixed-citation publication-type="other">Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, <etal>et al</etal>. (2011) The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement.</mixed-citation>
              </ref>
              <ref id="pone.0047905-Berg1">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Berg</surname><given-names>L</given-names></name> (<year>1988</year>) <article-title>Clinical Dementia Rating (CDR)</article-title>. <source>Psychopharmacol Bull</source>
<volume>24</volume>: <fpage>637</fpage>–<lpage>639</lpage>.<pub-id pub-id-type="pmid">3249765</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Folstein1">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Folstein</surname><given-names>MF</given-names></name>, <name><surname>Folstein</surname><given-names>SE</given-names></name>, <name><surname>McHugh</surname><given-names>PR</given-names></name> (<year>1975</year>) <article-title>“Mini-mental state”</article-title>. A practical method for grading the cognitive state of patients for the clinician. <source>J Psychiatr Res</source>
<volume>12</volume>: <fpage>189</fpage>–<lpage>198</lpage>.<pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Wechsler1">
                <label>19</label>
                <mixed-citation publication-type="book">Wechsler D (1987) WMS-R Wechsler Memory Scale-Revised Manual. New York: The Psychological Corporation, Harcourt Brace Javanovick, Inc.</mixed-citation>
              </ref>
              <ref id="pone.0047905-Tierney1">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Tierney</surname><given-names>MC</given-names></name>, <name><surname>Fisher</surname><given-names>RH</given-names></name>, <name><surname>Lewis</surname><given-names>AJ</given-names></name>, <name><surname>Zorzitto</surname><given-names>ML</given-names></name>, <name><surname>Snow</surname><given-names>WG</given-names></name>, <etal>et al</etal> (<year>1988</year>) <article-title>The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases</article-title>. <source>Neurology</source>
<volume>38</volume>: <fpage>359</fpage>–<lpage>364</lpage>.<pub-id pub-id-type="pmid">3347338</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Jack2">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name><surname>Wiste</surname><given-names>HJ</given-names></name>, <name><surname>Vemuri</surname><given-names>P</given-names></name>, <name><surname>Weigand</surname><given-names>SD</given-names></name>, <name><surname>Senjem</surname><given-names>ML</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease</article-title>. <source>Brain</source>
<volume>133</volume>: <fpage>3336</fpage>–<lpage>3348</lpage>.<pub-id pub-id-type="pmid">20935035</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Worsley1">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Worsley</surname><given-names>KJ</given-names></name>, <name><surname>Taylor</surname><given-names>JE</given-names></name>, <name><surname>Tomaiuolo</surname><given-names>F</given-names></name>, <name><surname>Lerch</surname><given-names>J</given-names></name> (<year>2004</year>) <article-title>Unified univariate and multivariate random field theory</article-title>. <source>Neuroimage</source>
<volume>23</volume> Suppl 1<fpage>S189</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">15501088</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Morris1">
                <label>23</label>
                <mixed-citation publication-type="other">Morris J (2010) CDR ACTUAL PROTOCOL. 1–10.</mixed-citation>
              </ref>
              <ref id="pone.0047905-Soscia1">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Soscia</surname><given-names>SJ</given-names></name>, <name><surname>Kirby</surname><given-names>JE</given-names></name>, <name><surname>Washicosky</surname><given-names>KJ</given-names></name>, <name><surname>Tucker</surname><given-names>SM</given-names></name>, <name><surname>Ingelsson</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide</article-title>. <source>PLoS ONE</source>
<volume>5</volume>: <fpage>e9505</fpage>.<pub-id pub-id-type="pmid">20209079</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Villemagne1">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Villemagne</surname><given-names>VL</given-names></name>, <name><surname>Pike</surname><given-names>KE</given-names></name>, <name><surname>Chetelat</surname><given-names>G</given-names></name>, <name><surname>Ellis</surname><given-names>KA</given-names></name>, <name><surname>Mulligan</surname><given-names>RS</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease</article-title>. <source>Ann Neurol</source>
<volume>69</volume>: <fpage>181</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">21280088</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Sojkova1">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Sojkova</surname><given-names>J</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>An</surname><given-names>Y</given-names></name>, <name><surname>Kraut</surname><given-names>MA</given-names></name>, <name><surname>Ferrucci</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Longitudinal patterns of beta-amyloid deposition in nondemented older adults</article-title>. <source>Arch Neurol</source>
<volume>68</volume>: <fpage>644</fpage>–<lpage>649</lpage>.<pub-id pub-id-type="pmid">21555640</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Aizenstein1">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Aizenstein</surname><given-names>HJ</given-names></name>, <name><surname>Nebes</surname><given-names>RD</given-names></name>, <name><surname>Saxton</surname><given-names>JA</given-names></name>, <name><surname>Price</surname><given-names>JC</given-names></name>, <name><surname>Mathis</surname><given-names>CA</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Frequent amyloid deposition without significant cognitive impairment among the elderly</article-title>. <source>Arch Neurol</source>
<volume>65</volume>: <fpage>1509</fpage>–<lpage>1517</lpage>.<pub-id pub-id-type="pmid">19001171</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Engler1">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Engler</surname><given-names>H</given-names></name>, <name><surname>Forsberg</surname><given-names>A</given-names></name>, <name><surname>Almkvist</surname><given-names>O</given-names></name>, <name><surname>Blomquist</surname><given-names>G</given-names></name>, <name><surname>Larsson</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease</article-title>. <source>Brain</source>
<volume>129</volume>: <fpage>2856</fpage>–<lpage>2866</lpage>.<pub-id pub-id-type="pmid">16854944</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Jack3">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name><surname>Lowe</surname><given-names>VJ</given-names></name>, <name><surname>Weigand</surname><given-names>SD</given-names></name>, <name><surname>Wiste</surname><given-names>HJ</given-names></name>, <name><surname>Senjem</surname><given-names>ML</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease</article-title>. <source>Brain</source>
<volume>132</volume>: <fpage>1355</fpage>–<lpage>1365</lpage>.<pub-id pub-id-type="pmid">19339253</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Weigand1">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Weigand</surname><given-names>SD</given-names></name>, <name><surname>Vemuri</surname><given-names>P</given-names></name>, <name><surname>Wiste</surname><given-names>HJ</given-names></name>, <name><surname>Senjem</surname><given-names>ML</given-names></name>, <name><surname>Pankratz</surname><given-names>VS</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid</article-title>. <source>Alzheimers Dement</source>
<volume>7</volume>: <fpage>133</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">21282074</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Forsberg1">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Forsberg</surname><given-names>A</given-names></name>, <name><surname>Engler</surname><given-names>H</given-names></name>, <name><surname>Almkvist</surname><given-names>O</given-names></name>, <name><surname>Blomquist</surname><given-names>G</given-names></name>, <name><surname>Hagman</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>PET imaging of amyloid deposition in patients with mild cognitive impairment</article-title>. <source>Neurobiol Aging</source>
<volume>29</volume>: <fpage>1456</fpage>–<lpage>1465</lpage>.<pub-id pub-id-type="pmid">17499392</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Braak1">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Braak</surname><given-names>H</given-names></name>, <name><surname>Braak</surname><given-names>E</given-names></name> (<year>1991</year>) <article-title>Neuropathological stageing of Alzheimer-related changes</article-title>. <source>Acta Neuropathol</source>
<volume>82</volume>: <fpage>239</fpage>–<lpage>259</lpage>.<pub-id pub-id-type="pmid">1759558</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-DelSole1">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Del Sole</surname><given-names>A</given-names></name>, <name><surname>Clerici</surname><given-names>F</given-names></name>, <name><surname>Chiti</surname><given-names>A</given-names></name>, <name><surname>Lecchi</surname><given-names>M</given-names></name>, <name><surname>Mariani</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<volume>35</volume>: <fpage>1357</fpage>–<lpage>1366</lpage>.<pub-id pub-id-type="pmid">18418593</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Li1">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Rinne</surname><given-names>JO</given-names></name>, <name><surname>Mosconi</surname><given-names>L</given-names></name>, <name><surname>Pirraglia</surname><given-names>E</given-names></name>, <name><surname>Rusinek</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<volume>35</volume>: <fpage>2169</fpage>–<lpage>2181</lpage>.<pub-id pub-id-type="pmid">18566819</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Devanand1">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Devanand</surname><given-names>DP</given-names></name>, <name><surname>Mikhno</surname><given-names>A</given-names></name>, <name><surname>Pelton</surname><given-names>GH</given-names></name>, <name><surname>Cuasay</surname><given-names>K</given-names></name>, <name><surname>Pradhaban</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls</article-title>. <source>J Geriatr Psychiatry Neurol</source>
<volume>23</volume>: <fpage>185</fpage>–<lpage>198</lpage>.<pub-id pub-id-type="pmid">20430977</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Mosconi3">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Mosconi</surname><given-names>L</given-names></name> (<year>2005</year>) <article-title>Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD</article-title>. <source>Eur J Nucl Med Mol Imaging</source>
<volume>32</volume>: <fpage>486</fpage>–<lpage>510</lpage>.<pub-id pub-id-type="pmid">15747152</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Herholz1">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Herholz</surname><given-names>K</given-names></name> (<year>2010</year>) <article-title>Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease</article-title>. <source>Expert Rev Neurother</source>
<volume>10</volume>: <fpage>1667</fpage>–<lpage>1673</lpage>.<pub-id pub-id-type="pmid">20977325</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Lowe1">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Lowe</surname><given-names>VJ</given-names></name>, <name><surname>Kemp</surname><given-names>BJ</given-names></name>, <name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>, <name><surname>Senjem</surname><given-names>M</given-names></name>, <name><surname>Weigand</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Comparison of 18F-FDG and PiB PET in cognitive impairment</article-title>. <source>J Nucl Med</source>
<volume>50</volume>: <fpage>878</fpage>–<lpage>886</lpage>.<pub-id pub-id-type="pmid">19443597</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Edison1">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Edison</surname><given-names>P</given-names></name>, <name><surname>Archer</surname><given-names>HA</given-names></name>, <name><surname>Hinz</surname><given-names>R</given-names></name>, <name><surname>Hammers</surname><given-names>A</given-names></name>, <name><surname>Pavese</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study</article-title>. <source>Neurology</source>
<volume>68</volume>: <fpage>501</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">17065593</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Renner1">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Renner</surname><given-names>M</given-names></name>, <name><surname>Lacor</surname><given-names>PN</given-names></name>, <name><surname>Velasco</surname><given-names>PT</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Contractor</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5</article-title>. <source>Neuron</source>
<volume>66</volume>: <fpage>739</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">20547131</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Lacor1">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Lacor</surname><given-names>PN</given-names></name>, <name><surname>Buniel</surname><given-names>MC</given-names></name>, <name><surname>Furlow</surname><given-names>PW</given-names></name>, <name><surname>Sanz Clemente</surname><given-names>A</given-names></name>, <name><surname>Velasco</surname><given-names>PT</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>A Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease</article-title>. <source>The Journal of neuroscience : the official journal of the Society for Neuroscience</source>
<volume>27</volume>: <fpage>796</fpage>–<lpage>807</lpage>.<pub-id pub-id-type="pmid">17251419</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Cummings1">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Cummings</surname><given-names>JL</given-names></name>, <name><surname>Doody</surname><given-names>R</given-names></name>, <name><surname>Clark</surname><given-names>C</given-names></name> (<year>2007</year>) <article-title>Disease-modifying therapies for Alzheimer disease: challenges to early intervention</article-title>. <source>Neurology</source>
<volume>69</volume>: <fpage>1622</fpage>–<lpage>1634</lpage>.<pub-id pub-id-type="pmid">17938373</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0047905-Reiman1">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Reiman</surname><given-names>EM</given-names></name>, <name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Bandy</surname><given-names>D</given-names></name>, <name><surname>Yu</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>: <fpage>6820</fpage>–<lpage>6825</lpage>.<pub-id pub-id-type="pmid">19346482</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
